Time filter

Source Type

San Jose, CA, United States

OncoHealth | Date: 2012-12-11

Drug testing kits comprised of medical diagnostic reagents and assays for direct detection of human papillomavirus E6 and human papillomavirus E7 oncoproteins.

OncoHealth | Date: 2012-10-15

Drug testing kits comprised of medical diagnostic reagents and assays for direct detection of human papillomavirus E6 and human papillomavirus E7 oncoproteins.

Crawled News Article
Site: www.finsmes.com

OncoHealth Corporation, a Redwood City, CA-based developer of novel diagnostics for cervical cancer and other potentially deadly cancers caused by the human papillomavirus (HPV), has raised $1.6m in a Series A funding. The company intends to use the funds to participate in a comparative study currently being conducted by the federal government and a national reference laboratory to evaluate OncoHealth’s technology. “Companies trying to raise between $1 million and $4 million increasingly encounter a funding gap. The amount is too big for a single angel group and too small for most venture capitalists,” said Led by CEO Winnie Wan, Ph.D., OncoHealth plans to commercialize proprietary tests, which are designed to enable clinicians to triage HPV-infected patients based on their cancer-progression status and select the most effective treatments.

Martinez-Useros J.,OncoHealth | Garcia-Foncillas J.,OncoHealth
Journal of Translational Medicine

The huge part of population in developed countries is overweight or obese. Obesity is often determined by body mass index (BMI) but new accurate methods and ratios have recently appeared to measure body fat or fat located in the intestines. Early diagnosis of obesity is crucial since it is considered an increasing colorectal cancer risk factor. On the one hand, colorectal cancer has been strongly associated with lifestyle factors. A diet rich in red and processed meats may increase colorectal cancer risk; however, high-fiber diets (grains, cereals and fruits) have been associated with a decreased risk of colorectal cancer. Other life-style factors associated with obesity that also increase colorectal cancer risk are physical inactivity, smoking and high alcohol intake. Cutting-edge studies reported that high-risk transformation ability of adipose tissue is due to production of different pro-inflammatory cytokines like IL-8, IL-6 or IL-2 and other enzymes like lactate dehydrogenase (LDH) and tumour necrosis factor alpha (TNFaα). Furthermore, oxidative stress produces fatty-acid peroxidation whose metabolites possess very high toxicities and mutagenic properties. 4-hydroxy-2-nonenal (4-HNE) is an active compounds that upregulates prostaglandin E2 which is directly associated with high proliferative colorectal cancer. Moreover, 4-HNE deregulates cell proliferation, cell survival, differentiation, autophagy, senescence, apoptosis and necrosis via mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PIK3CA)-AKT and protein kinase C pathways. Other product of lipid peroxidation is malondialdehyde (MDA) being able to regulate insulin through WNT-pathway as well as having demonstrated its mutagenic capability. Accumulation of point mutation enables genomic evolution of colorectal cancer described in the model of Fearon and Vogelstein. In this review, we will summarize different determination methods and techniques to assess a truthfully diagnosis and we will explain some of the capabilities that performs adipocytes as the largest endocrine organ. © 2016 Martinez-Useros and Garcia-Foncillas. Source

OncoHealth | Date: 2012-01-09

cELISA is a name of tests for direct detection of biomarkers in whole cell on enzyme immuno assay platform.

Discover hidden collaborations